Zymeworks Inc.

Zymeworks Bc Inc.

Var2 Pharmaceuticals Aps

James R Rich

Geoffrey C Winters

Tom Han Hsiao Hsieh

Alexander Laurence Mandel

Stuart Daniel Barnscher

Elyse Marie Josée Bourque

John Stephen Babcook

Bradley John Hedberg

Graham Albert Edwin Garnett

Rupert H Davies

Tom Han Hsieh

Mads Daugaard

Gerald J Rowse

Ali El-Salanti

Vincent K C Fung

Kevin Hamblett

Elyse Marie Bourque

Dunja Urosev

Madeleine Dahlback

Jan Peter Bergqvist

Michael G Brant

Danny Chui

Ada G H Young

Samuel Oliver Lawn

Andrea Hernandez Rojas

Raffaele Colombo

Samir Das

Mark Edmund Petersen

Robert William Gene

Duncan Browman

Peter Wing Yiu Chan

Sukhbir Singh Kang

Brandon Clavette

Elyse Marie Josee Bourque

Manuel Michel Auguste Lasalle

Alexander L Mandel

Tom Han Hsiao Hsie

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

Antibody-drug conjugates targeting folate receptor alpha and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.

Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Cytotoxic and anti-mitotic compounds, and methods of using the same

Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.

Sulfonamide-containing linkage systems for drug conjugates

The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.

Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (&#x3c;3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR&#x2265;3.9 when administered at the same toxin dose.

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.

VAR2CSA-drug conjugates

VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.

Compositions and methods for the treatment of platinum-drug resistant cancer

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Growing community of inventors

Vancouver, Canada

James R Rich